vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Gen Digital (GEN). Click either name above to swap in a different company.
Gen Digital is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× Elanco Animal Health Inc). Gen Digital runs the higher net margin — 15.5% vs -24.1%, a 39.6% gap on every dollar of revenue. On growth, Gen Digital posted the faster year-over-year revenue change (28.5% vs 12.2%). Over the past eight quarters, Gen Digital's revenue compounded faster (13.2% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Gen Digital Inc. is a multinational software company co-headquartered in both Tempe, Arizona (USA) and Prague, Czech Republic (EU). The company provides cybersecurity software, financial technology, and services. Gen is a Fortune 500 company and a member of the S&P 500 stock-market index. It is listed at both NASDAQ and Prague Stock Exchange. Its portfolio includes Norton, Avast, LifeLock, Avira, AVG, ReputationDefender, MoneyLion and CCleaner.
ELAN vs GEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $-276.0M | $192.0M |
| Gross Margin | 51.5% | 78.4% |
| Operating Margin | -22.6% | 34.9% |
| Net Margin | -24.1% | 15.5% |
| Revenue YoY | 12.2% | 28.5% |
| Net Profit YoY | -3350.0% | 6.1% |
| EPS (diluted) | $-0.55 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | $1.0B | ||
| Q4 24 | $1.0B | $986.0M | ||
| Q3 24 | $1.0B | $974.0M | ||
| Q2 24 | $1.2B | $965.0M |
| Q1 26 | — | $192.0M | ||
| Q4 25 | $-276.0M | $134.0M | ||
| Q3 25 | $-34.0M | $135.0M | ||
| Q2 25 | $11.0M | — | ||
| Q1 25 | $67.0M | $142.0M | ||
| Q4 24 | $-8.0M | $159.0M | ||
| Q3 24 | $364.0M | $161.0M | ||
| Q2 24 | $-50.0M | $181.0M |
| Q1 26 | — | 78.4% | ||
| Q4 25 | 51.5% | 78.2% | ||
| Q3 25 | 53.4% | 78.8% | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | 80.3% | ||
| Q4 24 | 50.9% | 80.4% | ||
| Q3 24 | 52.2% | 80.1% | ||
| Q2 24 | 58.2% | 80.3% |
| Q1 26 | — | 34.9% | ||
| Q4 25 | -22.6% | 35.9% | ||
| Q3 25 | -4.4% | 35.5% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 5.0% | 41.3% | ||
| Q4 24 | -5.0% | 37.9% | ||
| Q3 24 | 54.3% | 41.3% | ||
| Q2 24 | -2.7% | 43.2% |
| Q1 26 | — | 15.5% | ||
| Q4 25 | -24.1% | 11.0% | ||
| Q3 25 | -3.0% | 10.7% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 5.6% | 14.1% | ||
| Q4 24 | -0.8% | 16.1% | ||
| Q3 24 | 35.3% | 16.5% | ||
| Q2 24 | -4.2% | 18.8% |
| Q1 26 | — | $0.31 | ||
| Q4 25 | $-0.55 | $0.21 | ||
| Q3 25 | $-0.07 | $0.22 | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.13 | $0.22 | ||
| Q4 24 | $-0.01 | $0.26 | ||
| Q3 24 | $0.73 | $0.26 | ||
| Q2 24 | $-0.10 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | — |
| Total DebtLower is stronger | $3.9B | $8.4B |
| Stockholders' EquityBook value | $6.5B | $2.3B |
| Total Assets | $13.4B | $15.8B |
| Debt / EquityLower = less leverage | 0.60× | 3.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | $1.0B | ||
| Q4 24 | $468.0M | $883.0M | ||
| Q3 24 | $490.0M | $737.0M | ||
| Q2 24 | $416.0M | $644.0M |
| Q1 26 | — | $8.4B | ||
| Q4 25 | $3.9B | $8.7B | ||
| Q3 25 | $4.0B | $8.9B | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | $8.3B | ||
| Q4 24 | $4.3B | $8.5B | ||
| Q3 24 | $4.4B | $8.5B | ||
| Q2 24 | $5.7B | $8.5B |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $6.5B | $2.5B | ||
| Q3 25 | $6.7B | $2.4B | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $6.4B | $2.3B | ||
| Q4 24 | $6.1B | $2.2B | ||
| Q3 24 | $6.5B | $2.1B | ||
| Q2 24 | $5.9B | $2.0B |
| Q1 26 | — | $15.8B | ||
| Q4 25 | $13.4B | $16.1B | ||
| Q3 25 | $13.6B | $16.4B | ||
| Q2 25 | $13.7B | — | ||
| Q1 25 | $12.9B | $15.5B | ||
| Q4 24 | $12.6B | $15.4B | ||
| Q3 24 | $13.3B | $15.5B | ||
| Q2 24 | $13.8B | $15.4B |
| Q1 26 | — | 3.61× | ||
| Q4 25 | 0.60× | 3.54× | ||
| Q3 25 | 0.59× | 3.75× | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | 3.64× | ||
| Q4 24 | 0.70× | 3.94× | ||
| Q3 24 | 0.67× | 4.06× | ||
| Q2 24 | 0.96× | 4.33× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $541.0M | ||
| Q3 25 | $219.0M | $409.0M | ||
| Q2 25 | $237.0M | — | ||
| Q1 25 | $-4.0M | $473.0M | ||
| Q4 24 | $177.0M | $326.0M | ||
| Q3 24 | $162.0M | $158.0M | ||
| Q2 24 | $200.0M | $264.0M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $535.0M | ||
| Q3 25 | $127.0M | $405.0M | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $-69.0M | $470.0M | ||
| Q4 24 | $130.0M | $318.0M | ||
| Q3 24 | $120.0M | $156.0M | ||
| Q2 24 | $166.0M | $262.0M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 43.9% | ||
| Q3 25 | 11.2% | 32.2% | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | -5.8% | 46.5% | ||
| Q4 24 | 12.7% | 32.3% | ||
| Q3 24 | 11.7% | 16.0% | ||
| Q2 24 | 14.0% | 27.2% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 0.5% | ||
| Q3 25 | 8.1% | 0.3% | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 5.4% | 0.3% | ||
| Q4 24 | 4.6% | 0.8% | ||
| Q3 24 | 4.1% | 0.2% | ||
| Q2 24 | 2.9% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.04× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | 3.33× | ||
| Q4 24 | — | 2.05× | ||
| Q3 24 | 0.45× | 0.98× | ||
| Q2 24 | — | 1.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
GEN
| Cyber Safety Platform | $819.0M | 66% |
| Trust Based Solutions | $421.0M | 34% |
| Net Interest Income On Notes Receivable | $4.0M | 0% |
